Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. - Wikidata - wikimedia - TriplyDB

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.

http://www.wikidata.org/entity/Q34627112

about

Surgery for Non-Hodgkin's Lymphoma How I treat HIV-associated lymphoma Burkitt lymphoma in adolescents and young adults: management challenges.Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study.Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Burkitt's lymphoma masquerading as appendicitis--two case reports and review of the literature Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome.Primary cardiac burkitt lymphoma presenting with abdominal pain.Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis.Effect of rituximab on adult Burkitt's lymphoma: a systematic review and meta-analysis.Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers.Low-intensity therapy in adults with Burkitt's lymphoma.Primary Burkitt lymphoma of the supraglottic larynx: a case report and review of the literature.Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.The role of hematopoietic SCT in adult Burkitt lymphoma.Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.Therapeutic approaches to haematological malignancies in adolescents and young adults.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.Treating Burkitt Lymphoma in Adults.Diagnosis and treatment of CD20 negative B cell lymphomas.Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database.Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013.Jejunal Perforation: A Rare Presentation of Burkitt's Lymphoma-Successful Management.Peripheral blood lymphocyte to monocyte ratio identifies high-risk adult patients with sporadic Burkitt lymphoma.Early relapse of Burkitt lymphoma heralded by a bone marrow necrosis and numb chin syndrome successfully treated with allogeneic stem cell transplantation.Head and Neck Lymphomas in HIV Patients: a Clinical Perspective.Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.

P2860

Q26771421-C443C885-5734-4072-B3B6-07D5241F5FEF Q26821860-9A3289E8-B7DF-42D4-B322-9AD3E60863CA Q30238965-8F0FDDAC-9BD3-4544-BCF7-3A413A33FF42 Q30540646-75561B7D-4EA7-4212-BA85-703E7E2498B6 Q33411059-C55D1544-C3A3-4424-9019-5D68656BD7D8 Q33441858-E49FF5BD-CD59-45E8-8BC3-B6157FD2894F Q33673144-73A62C98-2521-40C3-A5FF-0845B23311B2 Q33823095-6EC8B88D-DCF7-4EE1-9D60-1D750BC8DF00 Q34344942-C6176B4B-C015-46A0-9F15-3825EDF2F444 Q34347222-CCAB897E-BA5D-494E-90A2-F3A1CF64CC8B Q34560650-FCD293BD-1E79-43F6-B85E-44D071233DB7 Q34737471-864E707E-03AD-413A-8B76-95FAC43AA32C Q35021459-F2DFF00E-4DB4-413E-9E80-E9B5EDFD8F2F Q35429833-D66157AB-B90D-4796-895F-0781D30908A1 Q35794300-9B9C0DF0-F5AD-43C4-B2AC-EB0F1777192C Q36557585-2CE11264-6E65-4687-A458-569DF782454C Q36620507-E6272C51-7581-4398-81A2-495DFDBD8201 Q37273182-935FAC5A-B531-4D53-9B9A-8E5AFB92BCBB Q37476684-3094C562-9CE7-4DFC-8FC6-80BB688CBB29 Q37511989-3FB21BF1-D737-4039-81CE-2CF6664C4568 Q37692622-35167C4B-3A15-475F-99D8-724FB865E4F8 Q37718297-04533D14-E537-43D2-B795-053C922FDE2B Q38031733-272F6EAE-6740-45B0-8839-9262FE3E9C1C Q38096425-8F14EBAE-BCB8-45AD-952B-6A05A54C46ED Q38134399-AB85FC46-E316-4B0E-AA54-0AC96EBEF5AC Q38394272-59C878D3-4D96-45EE-897F-F211F693F11D Q38465823-7604EA58-C0D7-49CA-B811-B614989E616F Q38503297-FB858285-8FDD-4F85-AAAD-F4C827B5302E Q39132786-3F85F1F3-2BE3-47C4-88F9-34E2E573C0FB Q39270336-D02AEEFB-A0FA-49B2-BBB1-1EA85174ACC2 Q39372883-F57B62E0-7956-43AA-BFB2-996007A12BB3 Q40071847-2EC75A0E-EE71-471E-8A6C-F967B401FE37 Q40411469-11FDD686-9165-4089-9AB4-AE11BFC1343F Q40960748-1004B35D-C7C6-4F8F-80EA-6909D3184213 Q41663533-0DFE5BA0-43B2-41AA-90D0-8B731E10F01B Q41761179-4FF87E67-4105-4677-A1C6-3BFF034B3015 Q41919568-F93CDDA9-3B5D-47F2-AFEA-45B1B0734883 Q42277126-1BF3BA20-2E4C-4371-9DC3-094625C4E369 Q43752446-124C559A-E1B7-4967-B3F0-AFD9AD8EE14B Q47361098-DDC7446C-0884-49C3-821C-D2C82235D0B4

P2860

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.

http://www.wikidata.org/entity/Q34627112

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Evaluation of the addition of ...... oma: a retrospective analysis.

@ast

Evaluation of the addition of ...... oma: a retrospective analysis.

@en

Evaluation of the addition of ...... oma: a retrospective analysis.

@nl

type

label

Evaluation of the addition of ...... oma: a retrospective analysis.

@ast

Evaluation of the addition of ...... oma: a retrospective analysis.

@en

Evaluation of the addition of ...... oma: a retrospective analysis.

@nl

prefLabel

Evaluation of the addition of ...... oma: a retrospective analysis.

@ast

Evaluation of the addition of ...... oma: a retrospective analysis.

@en

Evaluation of the addition of ...... oma: a retrospective analysis.

@nl

P1433

Q34627112-901864F3-C499-4926-A17C-55A995722874

P1476

Q34627112-49527343-1F81-4BC7-A095-F7BA7D8BB068

P2093

Q34627112-1A55C522-F771-436D-A1E8-A1258C1C3C36

Q34627112-1C7B31AD-961D-44FA-9A14-BF87EEC10BAD

Q34627112-1F51342C-7FF5-4738-8C21-0D4817E87002

Q34627112-525BDDC1-FFD0-48BC-BE52-BD9F6757D9EE

Q34627112-54A94EB1-444E-4662-8D75-50553C21D50D

Q34627112-5ED08A04-59DD-4BD9-BCF3-0C6D929D2FC2

Q34627112-7A0B22B1-5BB6-4286-958B-F4C692656992

Q34627112-803C05D4-7BE5-47F9-8E7C-9EB5B17AF32A

P2860

Q34627112-25BB8952-CB4E-44FF-845C-C3A219CA652A

Q34627112-3D02C462-FDB2-46A6-884C-F75219BD1FA5

Q34627112-499D3A5F-3C39-4944-9EC8-4BDAA5D0C222

Q34627112-53D52C7E-B534-4B1F-84DE-098F2466B234

Q34627112-631BD2A2-CB87-4AF4-9779-9E73F29BFFE6

Q34627112-6AD6B304-3E77-4E73-8663-768C64F7E12C

Q34627112-82378468-1C6D-4F93-9C2A-C94695D1BEA4

Q34627112-8B314BDB-D6E3-4718-B41B-09E01E8A3CC7

Q34627112-99AE3F21-4429-4AC6-BCC2-2B90CB037026

Q34627112-9BEDB5D7-A389-471A-9357-12E347A78E9F

P304

Q34627112-6CDE05A6-9280-4AAD-9590-B69D230EA7B9

P31

Q34627112-13E05EED-F8B5-44B0-A798-B3220A4947FA

P356

Q34627112-3CC97BDE-1B7B-4BC4-966A-0988AEF0F4D9

P433

Q34627112-B160A885-7C98-452F-B0A1-A377844C825C

P478

Q34627112-CAFE6726-E6AB-4B3E-AEC8-8FB85093DCD8

P577

Q34627112-81BDAC6A-4DDF-4232-A281-718834BB8A82

P5875

Q34627112-24647B90-5E1B-4FE8-9F4F-DAB6E0817CC4

P698

Q34627112-32470FFD-62A0-4F6E-BAB7-C70154C2602A

P921

Q34627112-156A3A8D-0BBC-4DE4-BA9D-F4DC274234B5

P356

P1433

Annals of Oncology

P1476

Evaluation of the addition of ...... oma: a retrospective analysis.

@en

P2093

A S Lacasce

http://www.w3.org/2001/XMLSchema#string

C E Toomey

http://www.w3.org/2001/XMLSchema#string

D Neuberg

http://www.w3.org/2001/XMLSchema#string

E P Hochberg

http://www.w3.org/2001/XMLSchema#string

J A Barnes

http://www.w3.org/2001/XMLSchema#string

J S Abramson

http://www.w3.org/2001/XMLSchema#string

J S Michaelson

http://www.w3.org/2001/XMLSchema#string

Y Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

P304

1859-1864

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDQ677

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49853461

http://www.w3.org/2001/XMLSchema#string

P698

21339382

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma